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Abstract: Multiple sclerosis (MS) is an autoimmune and demyelinating disease of the central
nervous system. Although the etiology of MS is still unknown, both genetic and environmental
factors contribute to the pathogenesis of the disease. Acetylcholine participates in the modulation
of central and peripheral inflammation. The cells of the immune system, as well as microglia,
astrocytes and oligodendrocytes express cholinergic markers and receptors of muscarinic and
nicotinic type. The role played by acetylcholine in MS has been recently investigated. In the
present review, we summarize the evidence indicating the cholinergic dysfunction in serum and
cerebrospinal fluid of relapsing–remitting (RR)-MS patients and in the brains of the MS animal
model experimental autoimmune encephalomyelitis (EAE). The correlation between the increased
activity of the cholinergic hydrolyzing enzymes acetylcholinesterase and butyrylcholinesterase, the
reduced levels of acetylcholine and the increase of pro-inflammatory cytokines production were
recently described in immune cells of MS patients. Moreover, the genetic polymorphisms for both
hydrolyzing enzymes and the possible correlation with the altered levels of their enzymatic activity
have been also reported. Finally, the changes in cholinergic markers expression in the central nervous
system of EAE mice in peak and chronic phases suggest the involvement of the acetylcholine also in
neuro-inflammatory processes.
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1. Acetylcholine and Immune System
Acetylcholine (ACh) is known as one of the main neurotransmitters in the central (CNS) and the
peripheral nervous system (PNS) [1]. It plays relevant roles in several organisms: in multicellular
organisms and in particular in mammalian species, it mediates the communication between the
nervous system and several peripheral organs such as muscle cells, heart, glands, gut, etc.....[2,3].
Interestingly, ACh can be produced also by non-neuronal cells, such as keratinocytes and endothelial
cells, contributing to local regulation of the cell physiology [4–6].
Evidence has been accumulated over the past 20 years on the ability of immune cells to respond to
cholinergic stimuli, focusing on the cholinergic modulation of the immune response and inflammatory
processes both in the immune system and in the brain [7,8].
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The first evidence suggested that the vagus nerve was responsible of the control of immune
cells responses by inflammatory reflex mediated by the cholinergic stimulation [9]. Albeit the vagus
nerve stimulation can modulate the peripheral inflammation, it has been proposed that it may control
ACh production directly by the immune cells in the spleen or in other lymphoid organs through
adrenergic stimulation [10,11]. This hypothesis appears more realistic considering that the ACh has
an extremely short half-life in vivo as a consequence of the ubiquitous distribution of its hydrolytic
enzymes acetylcholinesterase (AChE) and butirylcholinesterase (BChE) [12], which rapidly degrade it.
Therefore, the cholinergic source of ACh must be very close to the site of action (paracrine function).
It has been shown that several immune cells are able to produce ACh and to respond to cholinergic
stimuli. T and B cells, macrophages and dendritic cells (DCs) express most of the components of the
cholinergic system [13,14]. The presence of choline acetyltransferase (ChAT) and AChE in immune
cells has been demonstrated by different techniques [8,15,16]. Immunological activation of T cells
up-regulates cholinergic activity, as well as the toll-like receptor activation by selective agonists, induces
ChAT expression in DCs and macrophages [7]. These data support a clear cholinergic involvement in
the regulation of the immune functions.
The acetylcholine signaling in the immune system is mediated by two types of cholinergic
receptors: the muscarinic and nicotinic receptors.
The muscarinic receptors (mAChRs) are metabotropic receptors able to activate different signal
transduction pathways [17]. The immune cells express muscarinic receptors whose selective activation
modulates the synthesis and production of pro-inflammatory cytokines contributing to modulating the
inflammatory processes and, albeit they are not involved in the regulation of the antibodies’ synthesis,
they favor the antibody class switching from IgM to IgG1 [18,19].
Nicotinic receptors (nAChRs) are classical ionotropic receptors. The immune cells express different
nicotinic receptor subunits (α2, α4, α 5, α9, α7 and β1, β2) whose combination contributes to the
hetero- or homopentameric receptor subtype formation. The expression of these receptors is differently
distributed in the immune cells and in some cases correlates with their differentiation state [20].
The homopentameric α7 nAChR is the best characterized nicotinic receptor subtype in the immune
system. This receptor appears mainly involved in the inhibition of inflammatory processes modulating
the production of the anti-inflammatory cytokine, suppressing dendritic cells and macrophage activity
and leading to the suppression of T cell differentiation [21,22].
Considering the relevant role of the ACh and its receptors in immune cells functions and in the
modulation of the inflammatory processes, it is not difficult to hypothesize that a better understanding
of the roles played by ACh and its receptors in inflammatory-related diseases such as neurodegenerative
diseases, is of great clinical relevance.
In the present review, we summarize the data indicating the possible involvement of ACh also in
demyelinating disease such as multiple sclerosis (MS), reporting recent data demonstrating how the
alteration of the cholinergic system activity is present in MS patients and in experimental autoimmune
encephalomyelitis (EAE) mice, may be correlated with the immune system dysfunction and alterations
of the neuro-inflammatory processes characterizing the MS pathology.
2. Cholinergic Dysfunction in Multiple Sclerosis
MS is an autoimmune disease characterized by demyelination and chronic inflammation.
The progressive phases of the disease are associated with myelin sheets alteration and degradation and
decreased oligodendrocyte differentiation. The involvement of the cholinergic system in MS is poorly
known. However, several studies on EAE mice have suggested how the treatment with cholinesterase
inhibitors may improve motor and cognitive impairment and reduce the neuro-inflammation [23].
These effects were significantly abolished by α7 nAChR antagonists [24]. Moreover, as reviewed by
Nizri and Brenner [25], the α7 nAChRs also play a relevant role in the immune system where they
control the number of dendritic cells and the proliferation of the autoreactive T cells [26].
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According to this evidence, the ACh production and cholinergic marker expression and activity in
serum and cerebrospinal fluid (CSF) of MS patients were reported [27]. The first data have demonstrated
that ACh levels were significantly lower in MS patients with a relapsing–remitting course of the disease
(RR-MS) compared with healthy subjects (HS), both in sera and CSF [27,28]. However, no relationship
was found between ACh levels and patient gender or demographic and clinical aspects [27].
Interestingly the enzymatic activity of the ACh hydrolyzing enzymes AChE and BChE resulted
significantly increased in sera of MS patients [29]. The studies of the expression of AChE and
BChE transcripts in peripheral blood mononuclear cells (PBMC) of MS patients have demonstrated
an increase in the transcript levels of both hydrolyzing enzymes, in particular for BChE [28,29].
Moreover, the levels of ACh biosynthetic enzyme ChAT were higher in MS patients compared with
HS. Finally, the expression of transcript for OCTN-1 and mediatophore, the two proteins typically
expressed in immune cells and responsible for the non-vesicular ACh release were also upregulated in
MS patients [29].
These results suggest that the decreased levels of ACh observed in MS patients, may mainly be
dependent on the increased expression and activity of cholinergic hydrolyzing enzyme BChE and
AChE (Figure 1).
The dysregulated homeostasis of ACh has already been described in other neurological and
neurodegenerative diseases (i.e., schizophrenia, Alzheimer’s, Parkinson diseases) [30]. For these
pathologies, as well as for MS, it is difficult to understand whether the cholinergic dysregulation is the
cause or the effect of the pathology.
Interestingly, also some autoimmune diseases present alterations of cholinergic receptors
expression or activity (i.e., Sjogren’s disease, sepsis, myasthenia gravis) [31–33], confirming a relevant
role of cholinergic receptors also in immune system activity. Thus, the MS may be a new pathology
possibly correlated with cholinergic dysfunction.
3. The Interface between Cholinergic System and Inflammatory Cytokines in MS
Cytokines orchestrate all phases of immune responses, act in highly complex and dynamic
networks in a paracrine and/or autocrine manner and often perform overlapping and partly redundant
functions through multicomponent molecules that can be shared by different cell types. For the
homeostatic balance, a dynamic equilibrium between pro and anti-inflammatory cytokines is required.
Cytokines play a key role in the pathogenesis of MS through the activation of the immune system in
the periphery and in the central nervous system. Aberrant immune responses occur in MS and it is
likely that the spectrum of the cytokines produced decisively influences the outcome of the disease, as
evidenced by the cytokine profiles altered in the central nervous system [34] and in the biological fluid
of MS patients. As reported above, the serum levels of ACh were found to be lower in MS patients with
respect to levels detected in HS. Considering that ACh plays a central role in the crosstalk between
the immune and nervous system and that may act as a suppressor of inflammatory responses, the
relationship between the ACh synthesizing and degrading enzymes and pro-inflammatory cytokines
was evaluated. Interestingly, AChE and BChE are present at high levels in MS patients, contributing
to alter the steady-state equilibrium of the ACh [29]. The balance between the levels of pro- and
anti-inflammatory cytokines and their sequential release can be decisive for the severity of inflammatory
responses. Alteration of this balance can convert a beneficial effect into a pathological inflammatory
reaction. The well-known contribution of the inflammatory component to the progression of multiple
sclerosis has led to new attempts to discover ways to attenuate inflammation. The cholinergic system
has been suggested as a mediator of the crosstalk between the immune and nervous systems playing an
important role as a modulator of immune responses. The effect of dysregulated balance between ACh,
AChE and BChE on cytokines levels was studied in order to understand the role of the cholinergic
system on inflammatory environment present in MS patients. In the CSF and sera of RR-MS patients
and control subjects, the levels of IL-10 and IL-4 were evaluated and no statistical differences were
detected [27]. Conversely in both CSF and serum from RR-MS patients, the levels of IL-1β were
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significantly higher than those detected in CSF and serum of control subjects. Interesting, in both MS
and control groups, also the mean level of IL-17 was higher in the CSF than in serum, and serum levels
of IL-1β were about four times higher than in CSF of MS subjects. These data confirmed the active
pro-inflammatory state characterizing the MS patients [27,28,35]. Moreover, significant differences in
TNFα, IL-12/IL-23p40 and IL-18 levels were observed between MS patients and controls. However,
a not significant association between ACh hydrolyzing enzymes and the levels of these cytokines was
found [27,29].
However, in the serum of MS patients undergoing IFN-β treatment substantially lower levels of
IL-1β, IL-12/23p40, IL-18, TNF-α, and HMGB-1 and higher levels of IL-18BP and ACh were detected.
These results, other than reinforce the previous observation that a reduction in ACh levels is involved
in RR-MS and that ACh and circulating cytokines are mutually influenced [29], have suggested the
ability of IFN-β to modulate inflammatory cytokines also by restoring of the ACh levels [36].
ACh was present in inflammatory sites, probably synthesized from immune cells, and cytokines
produced to represent an inflammatory input signal to activate afferent vagus nerve fibers that transmit
information to the brain. Therefore, the cytokines produced by blood peripheral cells might affect the
function of the CNS by crossing the blood–brain barrier (BBB) for direct interaction with CNS tissue.
On the other hand, the cells of the immune systems may respond to neurotransmitters released by
autonomic nerves and communicate through neurotransmitters [11].
The higher gene expression level of several cytokines, such as IL-1β, IL-12/IL-23p40, IL-17, IL-18
and TNFα was detected in RR-MS compared to HS, according to with the levels measured in the serum;
this confirms the relationship between expression and production of pro-inflammatory cytokines in
MS patients [35].
These results led to evaluating which components of the cholinergic system could be relevant in
terms of the therapeutic tool in controlling the inflammatory state in MS patients. It is known that α7
nicotinic receptors stimulate the cholinergic anti-inflammatory pathway [37]. The expression of α7
and α4 nicotinic receptor subunits, in RR-MS patients and HS, was documented [35]. The expression
of the α7 receptor protein by western blot analysis, confirmed the gene expression data, showing
higher protein levels in MS patients. The stimulation with phytohaemagglutinin (PHA) was also
able to differently modulate the α7 nicotinic receptor expression in RR-MS patients and HS. In fact,
PHA stimulation significantly decreased mRNA levels for the α7 receptor subunit only in RR-MS
patients. Instead, the increased α7 nAChR expression after nicotine stimulation in PBMC of RR-MS
patients correlated with a reduction of the pro-inflammatory cytokines [35]. In fact, the ability of
nicotine to modulate the inflammatory cytokines in RR-MS patients was also evaluated. The effects
of nicotine on the production of IL-1β and IL-17 from PHA-stimulated PBMC of RR-MS and HS
were described. In both groups, nicotine decreased the levels of IL-1β and IL-17 released, but a more
significant decrease was observed in RR-MS patients. The expression of the cytokine transcript levels
after nicotine treatment was also evaluated [35]. In particular, the treatment of PBMC with PHA plus
nicotine significantly reduced the expression of IL-1β, especially in MS patients. Interestingly the
co-treatment of PBMC with PHA and 10 µM nicotine did not modify the expression of α7 subunit
mRNA in HS, while inducing a significant increase of α7 transcript levels in RR-MS patients [35].
Globally, these data suggest that the locally expressed and released components of the non-neuronal
cholinergic system may play paracrine or autocrine effects and contribute to modulate inflammatory
cytokines (Figure 1). This may suggest strategies involving the use of selective agonists of α7 nAChRs
in the modulation of the inflammatory responses also in demyelinating disease.
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about 15% of the patients with MS have an affected relative. Studies in twins reveal a concordance of 
25% in monozygotic twins and only 2.4% in dizygotic twins [41]. Recently, the following 
meta-analysis estimate was reported: 0.50 (95% CI: 0.39–0.61) for heritability, 0.21 (95% CI: 0.11–0.30) 
for shared environmental component and 0.29 (95% CI: 0.26–0.33) for unique environmental 
component [42]. The authors conclude that these results support the efforts to fill the gap of ‘missing 
heritability’ by genome-wide association studies (GWAS) on large populations as well as massive 
sequencing analysis by next-generation sequencing (NGS). The risk of developing the disease is 
15-fold higher when MS is present in a first-degree relative. Siblings of patients with MS have a risk 
of ~2.6%, parents have a risk of 1.8% and sons have a risk of ~1.5%. Accordingly, considering the 
distinction between monogenic and complex traits, no single gene or environmental factor causes 
MS and it does not follow the Mendelian model.  
MS is believed to be dependent on multiple independent or interacting polymorphism genes 
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4. Genetic Polymorphisms for BChE and AChE and MS
The etiology of MS can be considered multifactorial, based on the interaction between genetic and
several environmental factors (Figure 2). A hereditary basis of MS is suggested by epidemiological
studies. This can be supported by the recurrence risk of MS in twins, siblings, conjugal MS individuals,
and lower recurrence risk in adoptees [38–40]. In the general population, the risk of developing MS is
about 0.00125%, including the variability for geographic areas. Overall, about 15% of the patients with
MS have an affected relative. Studies in twins reveal a concordance of 25% in monozygotic twins and
only 2.4% in dizygotic twins [41]. Recently, the following meta-analysis estimate was reported: 0.50
(95% CI: 0.39–0.61) for heritability, 0.21 (95% CI: 0.11–0.30) for shared environmental component and
0.29 (95% CI: 0.26–0.33) for unique environmental component [42]. The authors conclude that these
results support the efforts to fill the gap of ‘missing heritability’ by genome-wide association studies
(GWAS) on large populations as well as massive sequencing analysis by next-generation sequencing
(NGS). The risk of developing the disease is 15-fold higher when MS is present in a first-degree relative.
Siblings of patients with MS have a risk of ~2.6%, parents have a risk of 1.8% and sons have a risk of
~1.5%. Accordingly, considering the distinction between monogenic and complex traits, no single gene
or environmental factor causes MS and it does not follow the Mendelian model.
MS is believed to be dependent on multiple independent or interacting polymorphism genes
with small or moderate effects, as well as their interaction with behavioral and environmental factors
(Figure 2) [43]. Several studies also aim to disclose the genetic basis of MS. For decades, only several
variants of the HLA antigen were known to have the strongest effect on the risk of MS [44,45]. Carrying
HLA-DRB1*1501 is associated with about three-fold greater odds of developing MS, while carrying
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HLA-A*02 is associated with meaningfully reduced odds. So far, genome-wide association studies,
carried out in populations worldwide, provided strong evidence for the association of approximately
>230 genetic variants. All these variants only account for 20% to 30% of MS heritability, suggesting that
its remaining part is likely related to epigenetic factors and gene-gene or gene-environment interactions.
Considerable attention has been focused on studies evaluating disease-modifying effects in MS that
identified genes such as the APOE, CXCR5, IL2RA, IL7R, IL7, IL12RB1, IL22RA2, IL12A, IL12B, IRF8,
TNFRSF1A, TNFRSF14, TNFSF14, CBLB, GPR65, MALT1, RGS1, RIC3, STAT3, TAGAP, TYK2, CYP27B1
and CYP24A1 [44,45].
Recently, it was reported in genome-wide association studies, that the implication of RIC3,
a chaperone of nAChRs, in multiple sclerosis (MS) and neuroinflammatory disease. RIC3 promotes the
functional expression of α7 nAChR, and it was shown a dynamic regulation of RIC3 in macrophages
and in lymphocytes, following an immune activation in human and murine cells.
Moreover, increased average expression of RIC3 and CHRNA7 in lymphocytes from MS patients
but not in healthy donors was observed. These data are consistent with a role for RIC3 and in its
regulated expression in inflammatory processes and in neuroinflammatory diseases [45].
The variation in some genes of the cholinergic system, such as those encoding BChE (gene BChE,
chrom. 3q26.1–q26.2) and AChE (gene AChE, chrom. 7q22.1) [http://www.genatlas.org] has also been
studied in MS patients in relation to altered levels of their enzymatic activity.
Variants in these genes have been largely investigated in relation to the onset of Alzheimer’s
disease [46,47], since the levels of these enzymes were found increased in the brains of patients, as well
as a number of low-grade systemic inflammation pathologies [48,49].
In particular, two specific polymorphisms within these genes have been studied, namely rs1803274
for BChE and rs2571598 for AChE. It is reported that rs1803274 for BChE is able to reduce the enzymes’
activity by about 30%–50% [50]. The BChE rs1803274 is characterized by a G/A substitution inducing the
Ala/Tr change at the codon 539 and it produces the so-called K-allele. This variation causes the reduction
of 30%–60% of ACh’s hydrolyzing activity and 30% of the capacity to hydrolyze butyryl-thiocholine.
BChE K-carriers, showing lowered hydrolytic activity of BChE K-allele, could potentially improve
cholinergic activity.
There are 19 single nucleotide polymorphisms (SNPs) for AChE [51]. The only rs1799806 on exon
6, a functional intronic C/T substitution, was associated with activity changes. The AChE activity of
homozygote Pro/Pro genotype was significantly lower than Arg/Arg genotypes. The presence of these
variants is controversially considered a risk factor for Alzheimer’s disease, as well as other conditions
such as stroke, Parkinson’s disease and related dementia [52,53]. Even if cholinergic neurotransmission
regulates the immune response and inhibits cytokine release after stroke, only the variant alleles of
BChE have been identified as risk factors for ischemic stroke [54] and associated with reduced BChE
activity in patients with post-stroke dementia (PSD) [49], while AChE rs1799806 do not influence the
AChE activity.
As above-described the ACh levels in serum of RR-MS patients were inversely correlated with the
increased activity of the hydrolyzing enzymes AChE and BChE [29]. The observed lower circulating
ACh levels in sera of MS patients are probably dependent on the higher activity of cholinergic
hydrolyzing enzymes [29].
In this context, it was recently investigated whether lower ACh concentration observed in RR-MS
compared to HS may be related to the ability to regulate the extracellular ACh levels, when needed,
or to the variation of AChE or BChE activity related to the association with rs1803274 for BChE and
rs2571598 for AChE genetic variations [55]. An association between the BChE K-allele and AChE
rs2571598 in 102 relapsing remitting-MS patients compared to 117 healthy controls was reported. These
data underlined that in RR-MS patients carrying the K-allele, higher BChE activity was observed [55].
Although this is in contrast with the reported role of this SNP in BChE gene, this excess of circulating
BChE removes ACh, negatively influencing the levels of all investigated pro-inflammatory cytokines
(Figure 1). Conceivably, other pathways, such as increased transduction of BChE, microRNAs or other
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gene modulators acting in combination with BChE-K, could be involved in the balance of the BChE
as well as a higher BChE enzymatic activity induced by the presence of the polymorphic allele may
reduce the amounts of circulating ACh.
These evidences may suggest that specific genetic endo-phenotypes are able to modulate the
pro-inflammatory immune responses in MS patients, altering the activity of AChE through ACh
hydrolysis. These data highlight the potential role of the non-neuronal cholinergic system in immune
cell function, even if studies on larger populations are needed in order to better discover MS etiology and
progression and to develop new disease-modifying therapies for MS with AChE and ACh as targets.
The reported literature about genetic biomarkers in MS is not always consistent in the worldwide
population. The detection of a single nucleotide polymorphism related to MS pathogenesis is very
hard given that several genetic polymorphisms are implicated, each with a small contribution to
the susceptibility or resistance to MS. Although numerous causal genes have been detected by
genome-wide association studies (GWAS), these susceptibility genes are linked to relatively low
disease risk, indicating the important role of environmental factors in the pathogenesis of the disease.
Next-generation sequencing (NGS) technology, with high-throughput capacity and accuracy, could be
a powerful tool to discover the genetic basis of MS. NGS can be applied to sequence analysis in any
part of the genome and the resulting transcriptome, including the whole genome, exons, and other
interesting regions, and accordingly can be roughly classified as whole-genome sequencing (WGS),
whole-exome sequencing (WES), RNA sequencing (RNA-seq), and DNA methylation sequencing.
So far, only rare variants of modest effect on MS risk affecting a subset of patients have been detected
by NGS including CYP27B1 and TYK2 genes [56,57]. Epigenetic mechanisms that have been detected
for MS pathogenesis are DNA methylation, histone modification and some microRNAs’ alternations.
Several cellular processes including apoptosis, differentiation and evolution can be modulated along
with epigenetic changes [58]. All these data support the idea of a complex basis of MS with clear
gene–environment interactions and epigenetic alterations triggered by environmental exposures in
individuals with a particular genetic profile (Figure 2) [59].
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Figure 2. Risk factors for multiple sclerosis (MS). A hereditary basis of MS is suggested by epidemiological
studies and recurrence risk of MS in twins, siblings, conjugal MS individuals. MS is believed to
result from multiple independent or interacting polymorphism genes as well as their interaction with
behavioral and environmental factors with strong, moderate, or weak effects. Epigenetic mechanisms
that have been detected for MS pathogenesis are DNA methylation, histone modification and some
microRNAs alternations.
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5. Cholinergic Markers Alteration in the Brain of EAE Mice
One of the animal models of MS, EAE can be obtained after active immunization with myelin
oligodendrocyte glycoprotein (MOG) 35–55 peptide as antigen in C57BL6 mice, and reproduces many
pathological features observed in MS [60]. Several days after immunization, it is possible to observe
immune cells infiltrating the CNS and activation of microglia. These events take place predominantly
in the spinal cord but also in other brain structures such as the cerebellum and the optic tract [61],
which lead to axonal damage and demyelination [62]. The MOG35-55-induced model of EAE is
characterized by the peak inflammatory phase, followed by a chronic phase of neurological deficit.
ACh may play a role in the development or in the remission of MS. Recent analyses of cholinergic
markers in the brain and spinal cord of EAE mice revealed specific alterations in their expression in
different brain areas and cellular populations associated to the different phases of the disease [63].
The mRNA coding for ChAT, the enzyme responsible for the synthesis of ACh from choline and
acetyl-CoA that serves as a marker of cholinergic cells, presents alterations in the expression levels
in different brain regions and spinal cord and in different disease phases of EAE mice [63]. Several
cholinergic nuclei of EAE mice in the chronic phase present an increment in ChAT expression levels
and an increase of the AChE activity and mRNA expression at peak of disease, suggesting that the
balance of ACh levels may contribute to the chronicity of the disease.
The BChE activity, a non-selective cholinesterase enzyme that catalyzes the ACh hydrolysis,
is altered in the habenula and solitary nucleus in both disease phases of EAE mice and in higher
proportion in astroglia and microglia/macrophage cells in the chronic group [63]. BChE activity
is detected in both glial cell populations and presents a significant increment in EAE animals in
the chronic phase compared to the peak phase or control brains. The high ratio of BChE to AChE
found in astrocytes of EAE mice in peak phase [63] may suggest this ratio as a potential marker for
brain areas selectively vulnerable to this neuropathology as it was described for Alzheimer’s disease
brains [64]. However, the treatment of EAE mice with a BChE/AChE inhibitor (rivastigmine) resulted
in an amelioration of the clinical symptoms associated also with a reduction in the demyelination [24],
supporting the role of BChE in neuroinflammation and demyelination (Figure 3).
As reported above, several studies show that α7 nAChR is the key subtype involved in
nAChR-mediated immune regulation [20,26,65]. α7 nAChR mRNA expression in the EAE chronic
group is increased in habenula and decreased in the dorsal tegmental nucleus. Conversely, the mRNA
levels of this receptor are increased in the dorsal tegmental nucleus of animals in the peak phase [63].
The altered expression of this receptor subunit in EAE mice during the chronic phase compared to the
peak phase of the disease may sustain its role in the neuro-inflammation regulation also in the brain
(Figure 3).
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6. Cholinergic Receptors in the Glial Cells
New ideas have emerged during the past several years on how the neurotransmitters, including
Ach, can actively participate in neuron–glia cross talk. This interaction is relevant both during
nervous system development to improve and address neuron and glial cell survival, proliferation
and differentiation, and in adulthood, to maintain axonal function and myelin integrity [66]. It is
now known that glial cells express receptors for different neurotransmitters, suggesting that these
molecules, most probably when released in extra-synaptic regions [67–69], may modulate glial cell
survival, proliferation, and myelination [67,70].
The expression of ACh receptors has been reported in several glial cells indicating these cells
as potential targets for ACh action [70,71]. Oligodendrocyte (OLs), the main target in MS, express
muscarinic receptors whose activation triggers different signal transduction pathways [67,70,72–74].
The presence of nicotinic receptor subunits (α3, a4, a5, a7, β2, and β4) was also revealed by RT-PCR
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and immunocytochemistry in oligodendrocytes precursor cells (OPC), but not in mature cells [75].
Oligodendrocytes express also acetylcholine muscarinic receptors. M1, M3, and M4 ACh receptors
were the muscarinic subtypes expressed in OPCs, whereas all five muscarinic receptor subtypes were
found to be expressed at low levels in mature OLs; thus muscarinic receptors favor the maintenance
of immature proliferating progenitor cells and counteract progression toward a mature state [75].
Accordingly, with this evidence, more recent research demonstrated that antagonists of muscarinic
receptors promote oligodendrocyte differentiation and rescue of the lesions in white matter in EAE
mice [76]. In fact benztropine, a typical muscarinic antagonist used as a drug for Parkinson’s disease
treatment has been proposed for MS treatment considering that MS symptoms in the EAE mouse model
were reverted [76,77]. Moreover, the benztropine appears to favor oligodendrocyte differentiation
and myelination by a specific antagonism of M1 and M3 receptors on oligodendrocyte precursor
cells (OPCs) [76]. Another important aspect to consider is that muscarinic receptors are able to
modulate pro-inflammatory cytokine production [18,28], so it may be possible to hypothesize that the
antagonism of muscarinic receptors can support not only oligodendrocyte differentiation but also the
neuro-inflammation decrease.
The presence of muscarinic receptors was demonstrated in cultured astrocytes [78] as well as the
expression of functional nAChRs subunits (a4, a7, β2, β3) has been reported in rat astrocytes [39,79].
In particular, the expression of a7 nAChR in astrocytes plays a relevant role in neuroprotection in
several neurodegenerative diseases (i.e., Alzheimer and Parkinson) [80,81].
Finally, microglia also express both muscarinic and nicotinic receptors. Zhang and collaborators [82]
described for the first time the expression of functional muscarinic receptors in human microglia.
Interestingly the upregulated expression of M3 receptor subtype in these cells causes an increase of
MHC-I and MHC-II expression, suggesting the pro-inflammatory microglia phenotype [83]. Microglia
also display nicotinic receptors, with a prevalence of a7 subunit [84–87]. For these reasons, this
nicotinic receptor subtype may be considered an interesting therapeutic target for several neurological
disorders considering its ability to modulate the cholinergic anti-inflammatory pathway and the
synaptic plasticity.
Taking all these into account, it cannot be excluded that cholinergic stimulation in the brain may
influence a complex network controlling both neuronal and glial functions and play a relevant role in
the control of the neuro-inflammation.
7. Conclusions
Understanding the mechanisms leading to aberrant immune response and the severe
neuro-inflammation in MS plays a relevant role in the development of new treatments directed
to decrease pro-inflammatory cytokine production and to ameliorate the clinical symptoms, slowing
the disease outcome and delaying or arresting the onset of the disabilities. In this review we
have presented recent data in EAE mice and in MS patients, supporting the role of ACh in MS.
The dysregulated ACh homeostasis in MS, suggest how its altered functions might represent an
additional pathogenetic mechanism negatively influencing the cytokines production with consequent
disease outcome.
Interestingly, using the EAE mice model, it has also been described as the alteration of ACh
synthesis or degradation may impact on neuron function, contributing to the motor and cognitive
disabilities characteristics of MS patients, also influencing the glia network, the differentiation and
survival of the oligodendrocytes, and triggering the neuro-inflammation.
The relevant role played by ACh in this context, is supported by the evidence that modulating
the cholinergic system activity or cholinergic receptor functions, the clinical disabilities, at least in
mice, are significantly reduced. In fact, the altered balance of ACh also in cholinergic area of the brain
or spinal cord of EAE mice (i.e., basal ganglia or spinal motoneuros), suggested that the decreased
ACh levels may influence the MS motor disabilities both reducing the levels of the neurotransmitter in
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the cholinergic neurons and increasing the neuro-inflammation with consequent impact on myelin
disruption and axonal conduction [63,76,77].
This aspect appears supported by additional studies performed with conventional drugs used in
the treatment of MS, as INFβ or dimethyl fumarate [36,88], that demonstrate a significant amelioration
of the cholinergic activity with a possible consequent reduction of the clinical symptoms-MS associated.
Therefore, further studies will be necessary to evaluate the impact of different immune modulators on
the cholinergic system activity both in the immune system and in the brain.
In conclusion, the data described in this review highlight as ACh and its receptors may be
implicated in MS pathogenesis. However, further investigation on the genetic aspects and epigenetic
modulation of cholinergic markers gene expression could significantly improve the knowledge about
MS onset and progression as well as to contribute to identifying new possible therapeutic strategies.
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